Genitourinary health
- 30 Nov 2023
- 1 Minute to read
- Print
- PDF
Genitourinary health
- Updated on 30 Nov 2023
- 1 Minute to read
- Print
- PDF
Article summary
Did you find this summary helpful?
Thank you for your feedback
- All vaginal oestrogen preparations have been shown to be effective at treating GSM.
- These treatments have been shown to decrease vaginal pH and reverse the microbiological changes that occur in the vagina following the menopause.
- Oestrogen also has a proliferative effect on the bladder and urethral epithelium and may help relieve symptoms of urinary frequency, urgency and possibly reduce the incidence of recurrent urinary tract infections.
- Symptoms of GSM are generally progressive without effective therapy and can have a significant adverse effect on a woman’s sexual health and quality of life.
- In the VIVA online survey of 3,520 postmenopausal women in 6 countries, 45% reported experiencing vaginal symptoms, and 75% felt that their symptoms negatively affected their lives.
References and Further Information:
- Hamoda H, Panay N, Pedder H et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Found on page 184. Post Reprod Health 2020.
- NAMS Position Statement. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. The Journal of the North American Menopause Society. 2020.
- Lethaby A, Ayeleke R, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. Vol. 8, no. CD001500, 2016.
- Baber R, Panay N, Fenton A and the IMS writing group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016. Found on page 116.
Was this article helpful?